Clinical trials
Microsatellite Stable Metastatic Colorectal Cancer clinical trials
Below are recruiting microsatellite stable metastatic colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 62 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07201519RecruitingPhase 2
Chemo infusion for liver cancer using a hybrid care model
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Lexington, KentuckyAges 18–99 - NCT06783569RecruitingPhase 1
First-in-human study for advanced solid tumors
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
Harbin, Heiljiang ProvinceAges 18 years+ - NCT07361107RecruitingPhase 1
Immune response study of histotripsy in colorectal cancer
This trial tests how your body's immune system reacts to a treatment called histotripsy for colorectal cancer that has spread to the liver. Histotripsy uses sound waves to break apart tumors, and the study aims to see if this can help your immune system fight the cancer better.
New Hyde Park, New YorkAges 18 years+ - NCT04421820RecruitingPhase 1/Phase 2
BOLD-100 with chemo for advanced gut cancer
This Phase 1/2 study tests whether BOLD-100, given with the standard chemo combination FOLFOX, can help people with advanced gastrointestinal cancers. It’s especially focused on specific tumor features (including BRAF status) and checks safety, dosing, and early signs of effectiveness.
Santa Monica, CaliforniaAges 18 years+ - NCT07281768RecruitingPhase 2
Chemo and immunotherapy for locally advanced rectal cancer
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Baltimore, MarylandAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT07262619RecruitingPhase 1/Phase 2
Study of EIK1005 for advanced solid tumors
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
Morristown, New JerseyAges 18 years+ - NCT07595874RecruitingPhase 2
New Immunotherapy Drugs Before Surgery for Advanced Colorectal Cancer
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.
Goodyear, ArizonaAges 18 years+ - NCT07058012RecruitingPhase 2
Testing immunotherapy for ctDNA-positive colorectal cancer after treatment
This trial is for people with colorectal cancer whose ctDNA blood test is still positive after surgery and chemotherapy. It tests two immunotherapy drugs (cemiplimab alone or with fianlimab) to see if they can eliminate the remaining cancer cells and prevent the cancer from coming back.
Gainesville, FloridaAges 18 years+ - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06555133RecruitingPhase 2
Study of Y-90, capecitabine, and atezolizumab for advanced colorectal cancer
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Providence, Rhode IslandAges 18 years+ - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+
Hear when a new Microsatellite Stable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for microsatellite stable metastatic colorectal cancer?
- Yes. Clin2 currently lists 62 recruiting microsatellite stable metastatic colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a microsatellite stable metastatic colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a microsatellite stable metastatic colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Microsatellite Stable Colorectal Carcinoma
- Microsatellite Stable Colorectal Cancer
- Metastatic Colorectal Cancer
- Metastatic Colorectal Cancer (CRC)
- Metastatic Colorectal Cancer (mCRC)
- Unresectable Metastatic Colorectal Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Microsatellite Stable Colorectal Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.